ABSTRACT
C-X-C motif chemokine receptor 4 (CXCR4), stromal cell-derived factor-1 (SDF-1), monocyte chemoattractant protein-1 (MCP-1), extracellular signal-regulated kinase 1/2 (ERK1/2) and nuclear factor-κB (NF-κB) affect bone cells and play an important role in bone and joint diseases, but the data on CXCR4, SDF-1, MCP-1, ERK1/2 and NF-κB in the serum of skeletal fluorosis (SF) patients are inconclusive. Thus, according to the "Diagnostic Criteria for Endemic Skeletal Fluorosis" (WS 192-2008), we enrolled patients with SF (n = 60) as the SF group and those without SF as the controls (n = 60). Serum levels of CXCR4, SDF-1, MCP-1, ERK1/2 and NF-κB were detected by enzyme-linked immunosorbent assays (ELISAs). Serum SDF-1, CXCR4, MCP-1 and NF-κB levels were significantly higher in the SF group than in the control group. Within the serum of SF patients, CXCR4 and SDF-1 levels were positively correlated with NF-κB levels. There was no correlation between MCP-1 levels and those of ERK1/2 or NF-κB. SDF-1 and CXCR4 may activate the NF-κB pathway, and MCP-1 affects the occurrence and development of SF by regulating osteocytes through other pathways. The SDF-1/CXCR4 axis and MCP-1 signalling pathway provide a new theoretical basis for the occurrence and development of SF.
Subject(s)
Bone Diseases , MAP Kinase Signaling System , NF-kappa B , Humans , Chemokine CCL2/blood , Mitogen-Activated Protein Kinase 3/blood , NF-kappa B/blood , Receptors, CXCR4/blood , Signal Transduction , Bone Diseases/blood , Bone Diseases/diagnosisABSTRACT
Natural killer (NK) cells preferentially accumulate at maternal-foetal interface and are believed to play vital immune-modulatory roles during early pregnancy and related immunological dysfunction may result in pregnant failure such as recurrent miscarriage (RM). However, the mechanisms underlying the establishment of maternal-foetal immunotolerance are complex but clarifying the roles of decidual NK (dNK) cells offers the potential to design immunotherapeutic strategies to assist RM patients. In this report, we analysed RNA sequencing on peripheral NK (pNK) and decidual NK cells during early pregnancy; we identified an immunomodulatory dNK subset CXCR4+ CD56bright dNK and investigated its origin and phenotypic and functional characteristics. CXCR4+ CD56bright dNK displayed a less activated and cytotoxic phenotype but an enhanced immunomodulatory potential relative to the CXCR4 negative subset. CXCR4+ CD56bright dNK promote Th2 shift in an IL-4-dependent manner and can be recruited from peripheral blood and reprogramed by trophoblasts, as an active participant in the establishment of immune-tolerance during early pregnancy. Diminished CXCR4+ dNK cells and their impaired ability to induce Th2 differentiation were found in RM patients and mouse models of spontaneous abortion. Moreover, adoptive transfer of CXCR4+ dNK cells to NK-deficient (Nfil3-/-) mice showed great therapeutic potential of CXCR4+ dNK via recovering the Th2/Th1 bias and reducing embryo resorption rates. The identification of this new dNK cell subset may lay the foundation for understanding NK cell mechanisms in early pregnancy and provide potential prognostic factors for the diagnosis and therapy of RM.
Subject(s)
Abortion, Habitual/prevention & control , Immune Tolerance/immunology , Killer Cells, Natural/immunology , Receptors, CXCR4/genetics , Receptors, CXCR4/immunology , Abortion, Habitual/blood , Abortion, Habitual/immunology , Animals , Decidua/immunology , Disease Models, Animal , Female , Humans , Male , Mice , Mice, Inbred BALB C , Neural Cell Adhesion Molecules/blood , Neural Cell Adhesion Molecules/genetics , Neural Cell Adhesion Molecules/immunology , Pregnancy , Pregnancy Trimester, First , Receptors, CXCR4/bloodABSTRACT
AIM: The chemokine-receptor axes play parts in development of leukemia, CXCL1, CXCL10 and CXCL12 are involved in immune responses. Thus, we have examined the serum levels of these chemokines in parallel with their related cognate receptors (CXCR1, CXCR3 and CXCR4) in AML (acute myeloid leukemia) patients prior and post BMT (bone marrow transplantation) therapy. MAIN METHODS: Clinical specimens were collected from 46 AML patients (23 M1 and 23 M3 subtypes) before/after BMT. CXCL1, CXCL10 and CXCL12 concentrations were determined by ELISA. The mRNA levels of the related receptors were detected by QRT_PCR. Data were analyzed by T-test, χ2 and ANOVA statistical methods in SPSS software version 18. A difference was regarded significant if P value < 0.05. KEY FINDINGS: Our results indicated that the elevated levels of CXCL12 in AML patients were remained unchanged after transplantation. The CXCL10 concentration was decreased in patients. All studied chemokines were elevated in BMT patients with history of 9 times PLT transfusion. In patients who received BMT from siblings CXCL1 and CXCL10 have been elevated, whereby they were compared to patients who received BMT from parents while CXCL12 sustained unchanged in groups. Serum measures of CXCL1 and CXCL10 were induced in acute and chronic GVHD patients in compare to these without GVHD. SIGNIFICANCE: According to the results, it can be concluded that these chemokines play fundamental parts in pathogenesis of both AML and BMT. It is worthy to note that chemokines could be used as diagnostic markers alongside with possible promising therapeutic targets.
Subject(s)
Bone Marrow Transplantation , Chemokine CXCL10/blood , Chemokine CXCL12/blood , Chemokine CXCL1/blood , Leukemia, Myeloid, Acute/blood , Leukemia, Myeloid, Acute/therapy , Adolescent , Adult , Biomarkers, Tumor/blood , Child , Child, Preschool , Female , Graft vs Host Disease/blood , Humans , Leukemia, Myeloid, Acute/pathology , Male , Postoperative Care , Preoperative Care , Receptors, CXCR3/blood , Receptors, CXCR4/blood , Receptors, Interleukin-8A/blood , Young AdultABSTRACT
[Figure: see text].
Subject(s)
Coronary Artery Disease/pathology , Obesity/pathology , Regeneration , Stem Cells/pathology , Vascular Remodeling , AC133 Antigen/blood , Adult , Antigens, CD34/blood , Biomarkers/blood , Cell Count , Coronary Artery Disease/blood , Coronary Artery Disease/mortality , Coronary Artery Disease/physiopathology , Female , Humans , Incidence , Leukocyte Common Antigens/blood , Male , Middle Aged , Obesity/blood , Obesity/mortality , Obesity/physiopathology , Phenotype , Prognosis , Receptors, CXCR4/blood , Registries , Risk Assessment , Risk Factors , Stem Cells/metabolism , Time FactorsABSTRACT
Leukocyte recruitment and heterocellular aggregate formation drive the inflammatory vaso-occlusive processes associated with sickle cell anemia (SCA). We characterized neutrophils in a population of patients with SCA and investigated whether platelet-derived molecules can induce phenotypic alterations in this cell type. Imaging flow cytometry analysis demonstrated that the frequency of circulating CXCR4hi neutrophils was significantly higher in steady-state SCA individuals than in healthy control individuals and that these cells presented increased CD11b activation and toll-like receptor-4 expression. SCA neutrophils display increased neutrophil-platelet aggregation, and CXCR4hi neutrophils demonstrated augmented neutrophil-platelet aggregate frequency with a higher mean number of platelets adhered per neutrophil. Importantly, incubation of neutrophils with platelets significantly elevated their CXCR4 expression, while SCA plasma was found to induce CXCR4hi neutrophil polarization significantly more than control plasma. SCA individuals had significantly increased plasma levels of serotonin (5-HT), and serotonin molecule and SCA plasma induced neutrophil CXCR4 expression in a serotonin-receptor-dependent manner. Thus, the augmented CXCR4hi neutrophil population may contribute to mechanisms that promote vaso-occlusion in SCA; furthermore, circulating serotonin, derived from platelet activation, may play a role in the polarization of neutrophils, suggesting that serotonin-receptor antagonists or serotonin reuptake inhibitors could represent therapeutic approaches to reduce neutrophil activation in SCA.
Subject(s)
Anemia, Sickle Cell/metabolism , Neutrophil Activation , Neutrophils/metabolism , Receptors, CXCR4/metabolism , Serotonin/blood , Anemia, Sickle Cell/blood , Anemia, Sickle Cell/immunology , Case-Control Studies , Cell Differentiation , Female , Flow Cytometry , Humans , Male , Receptors, CXCR4/bloodABSTRACT
BACKGROUND: The mortality rate of pancreatic cancer (PC) is equal to its incidence and the majority of PC patients die within a few months of diagnosis. Therefore, a search for new biomarkers useful in the diagnosis and prognosis of PC is ongoing. OBJECTIVES: The aim of our study was to compare the utility of CXCR2 and CXCR4 in the diagnosis and prediction of PC with classical tumor marker (carcinoembryonic antigen, CEA) and marker of inflammation-C-reactive protein (CRP). PATIENTS AND METHODS: The study comprised 64 subjects - 32 PC patients and 32 healthy volunteers. Serum concentrations of tested proteins were analysed using immunological methods. RESULTS: Serum CXCR2 and CXCR4 concentrations, similarly to those of CEA and CRP, were significantly elevated in PC patients compared to healthy controls. Moreover, concentrations of CXCR4 were significantly correlated with CXCR2 and CRP levels, while CRP concentrations were correlated with CXCR2 and CEA levels. The diagnostic sensitivity and the predictive value for negative (PV-ve) results for CXCR4 were similar to those of CEA and higher than those of CXCR2 and CRP, while the area under the ROC curve (AUC) for CXCR4 was the highest among all tested proteins (CXCR2, CEA, CRP). Moreover, serum CXCR2 was found to be a significant predictor of PC risk. CONCLUSIONS: CXCR4 is a better candidate for a tumor marker than CXCR2 in the diagnosis of PC, while serum CXCR2 is a significant predictor of PC risk.
Subject(s)
Biomarkers, Tumor/blood , Pancreatic Neoplasms/diagnosis , Receptors, CXCR4/blood , Receptors, Interleukin-8B/blood , Up-Regulation , Aged , Aged, 80 and over , C-Reactive Protein/metabolism , Carcinoembryonic Antigen/blood , Case-Control Studies , Early Detection of Cancer , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Middle Aged , Neoplasm Staging , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/pathology , Prognosis , Sensitivity and SpecificityABSTRACT
BACKGROUND: CXCR4, a transmembrane-receptor located on epithelial cells that is activated by CXCL12, may have a role in IPF via migration of CXCR4+ fibrocytes to the lung. However, its expression has not been fully characterised in idiopathic pulmonary fibrosis (IPF) or other fibrotic interstitial lung diseases (ILDs). CXCL12 is constitutively expressed in the bone marrow, and levels of CXCR4 regulate control of this signalling pathway. The aim of this study was to profile the expression of CXCR4 in lung tissue and peripheral circulation of patients with IPF and other fibrotic ILDs. METHODS: Expression of CXCR4 on peripheral blood mononuclear cells (PBMCs) was examined by flow cytometry in 20 patients with IPF and 10 age-matched non-disease control (NDC) donors. Levels of CXCL12 in human plasma were measured by ELISA. Expression of CXCR4, CXCL12, CD45, and e-cadherin was assessed in IPF (n = 10), other fibrotic ILD (n = 8) and NDC (n = 10) lung tissue by multiplex immunohistochemistry (OPAL) and slides were scanned using a Vectra 3 scanner. Cells were quantified with computer automated histological analysis software (HALO). RESULTS: In blood, the number of CXCR4+ cells was lower but the level of CXCL12 was higher in patients with IPF compared to NDC donors. Elevated CXCR4 expression was detected in lung tissue from patients with IPF and other fibrotic ILDs compared to NDC. There were higher levels of CXCR4+/e-cadherin+/CXCL12+ (epithelial) cells in IPF lung tissue compared to NDC, but there was no difference in the numbers of CXCR4+/CD45+/CXCL12+ (myeloid) cells between the two groups. CONCLUSIONS: This report demonstrates that CXCR4 is overexpressed not only in IPF but also in other ILDs and expression is particularly prominent within both honeycomb cysts and distal airway epithelium. This observation supports the hypothesis that CXCR4 may drive tissue fibrosis through binding its specific ligand CXCL12. Although CXCR4 expressing cells could be either of epithelial or myeloid origin it appears that the former is more prominent in IPF lung tissue. Further characterization of the cells of the honeycomb cyst may lead to a better understanding of the fibrogenic processes in IPF and other end-stage fibrotic ILDs.
Subject(s)
Idiopathic Pulmonary Fibrosis/blood , Idiopathic Pulmonary Fibrosis/diagnosis , Lung/metabolism , Lung/pathology , Receptors, CXCR4/blood , Aged , Biomarkers/blood , Female , Humans , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/pathology , Male , Middle AgedABSTRACT
BACKGROUND: Endothelial Progenitor cells (EPCs) has been shown to be dysfunctional in both type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) leading to poor regeneration of endothelium and renal perfusion. EPCs have been shown to be a robust cardiovascular disease (CVD) risk indicator. Cellular mechanisms of DPP4 inhibitors such as linagliptin (LG) on CVD risk, in patients with T2DM with established CKD has not been established. Linagliptin, a DPP4 inhibitor when added to insulin, metformin or both may improve endothelial dysfunction in a diabetic kidney disease (DKD) population. METHODS: 31 subjects taking metformin and/or Insulin were enrolled in this 12 weeks, double blind, randomized placebo matched trial, with 5 mg LG compared to placebo. Type 2 diabetes subjects (30-70 years old), HbA1c of 6.5-10%, CKD Stage 1-3 were included. CD34+ cell number, migratory function, gene expression along with vascular parameters such as arterial stiffness, biochemistry, resting energy expenditure and body composition were measured. Data were collected at week 0, 6 and 12. A mixed model regression analysis was done with p value < 0.05 considered significant. RESULTS: A double positive CD34/CD184 cell count had a statistically significant increase (p < 0.02) as determined by flow cytometry in LG group where CD184 is SDF1a cell surface receptor. Though mRNA differences in CD34+ve was more pronounced CD34- cell mRNA analysis showed increase in antioxidants (superoxide dismutase 2 or SOD2, Catalase and Glutathione Peroxidase or GPX) and prominent endothelial markers (PECAM1, VEGF-A, vWF and NOS3). Arterial stiffness measures such as augmentation Index (AI) (p < 0.04) and pulse wave analysis (PWV) were improved (reduced in stiffness) in LG group. A reduction in LDL: HDL ratio was noted in treatment group (p < 0.04). Urinary exosome protein examining podocyte health (podocalyxin, Wilms tumor and nephrin) showed reduction or improvement. CONCLUSIONS: In DKD subjects, Linagliptin promotes an increase in CXCR4 expression on CD34 + progenitor cells with a concomitant improvement in vascular and renal parameters at 12 weeks. Trial Registration Number NCT02467478 Date of Registration: 06/08/2015.
Subject(s)
Antigens, CD34/blood , Diabetes Mellitus, Type 2/drug therapy , Diabetic Nephropathies/drug therapy , Dipeptidyl-Peptidase IV Inhibitors/therapeutic use , Endothelial Progenitor Cells/drug effects , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Linagliptin/therapeutic use , Metformin/therapeutic use , Renal Insufficiency, Chronic/drug therapy , Adult , Aged , Biomarkers/blood , Cells, Cultured , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diagnosis , Diabetic Nephropathies/blood , Diabetic Nephropathies/diagnosis , Dipeptidyl-Peptidase IV Inhibitors/adverse effects , District of Columbia , Double-Blind Method , Drug Therapy, Combination , Endothelial Progenitor Cells/metabolism , Endothelial Progenitor Cells/pathology , Female , Humans , Hypoglycemic Agents/adverse effects , Insulin/adverse effects , Linagliptin/adverse effects , Male , Metformin/adverse effects , Middle Aged , Pilot Projects , Receptors, CXCR4/blood , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/diagnosis , Time Factors , Treatment OutcomeABSTRACT
We aimed to detect the MYD88L265P and CXCR4S338X mutations in cell-free DNA (cfDNA) in patients with Waldenström macroglobulinemia (WM). We collected peripheral blood and paired bone marrow aspirates from 27 WM patients (including 16 patients with newly diagnosed WM, 3 patients with WM in relapse and 8 patients with WM during treatment). cfDNA was extracted from peripheral blood using a QIAamp Circulating Nucleic Acid Kit. The MYD88L265P and CXCR4S338X mutations were detected by real-time allele-specific PCR (AS-PCR) in cfDNA and genomic DNA (gDNA) extracted from bone marrow aspirates. The sensitivity of real-time AS-PCR for detecting MYD88L265P in cfDNA was determined using a serial dilution of 10%, 2%, 0.4% and 0.08% MYD88L265P cfDNA in wild-type cfDNA. Among the 27 patients, MYD88L265P was detected in 88.9% of them in gDNA and in 85.2% of them in cfDNA, with a concordance rate of 96.3%. The concordance rates were 93.8%, 100% and 100% in patients with newly diagnosed WM, patients with WM in relapse and patients with WM during treatment, respectively. The sensitivity of real-time AS-PCR for detecting MYD88L265P in cfDNA was 0.4%. CXCR4S338X was detected in 6.3% of the 16 newly diagnosed WM patients in both gDNA and cfDNA, with a concordance rate of 100.0%. It is feasible to apply cfDNA to detect MYD88L265P and CXCR4S338X in WM patients with a high concordance rate.
Subject(s)
Cell-Free Nucleic Acids/genetics , Mutation, Missense , Myeloid Differentiation Factor 88/genetics , Neoplasm Proteins/genetics , Real-Time Polymerase Chain Reaction , Receptors, CXCR4/genetics , Waldenstrom Macroglobulinemia/genetics , Aged , Aged, 80 and over , Amino Acid Substitution , Cell-Free Nucleic Acids/blood , Female , Humans , Male , Middle Aged , Myeloid Differentiation Factor 88/blood , Neoplasm Proteins/blood , Receptors, CXCR4/blood , Sensitivity and Specificity , Waldenstrom Macroglobulinemia/blood , Waldenstrom Macroglobulinemia/therapyABSTRACT
There is evolving evidence that dysregulation of immune homeostasis in the bone marrow (BM) adjacent to the inflamed joints is involved in the pathogenesis of. In this study, we are addressing the phenotype and function of regulatory T cells (Tregs) residing in the BM of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). BM and peripheral blood samples were obtained from RA and OA patients undergoing hip replacement surgery. The number and phenotype of Tregs were analyzed by flow cytometry and immunohistochemistry. The function of Tregs was investigated ex vivo, addressing their suppressive activity on effector T cells. [3H]-Thymidine incorporation assay and specific enzyme-linked immunosorbent assay were used for quantification of cell proliferation and pro-inflammatory (TNF, IFN-γ) cytokine release, respectively. Significantly lower numbers of CD4+FOXP3+ T cells were found in the BM of patients with RA compared to control patients with OA. High expression of CD127 (IL-7 receptor) and relatively low expression of CXCR4 (receptor for stromal cell-derived factor CXCL12) are characteristics of the CD4+FOXP3+ cells residing in the BM of RA patients. The BM-resident Tregs of RA patients demonstrated a limited suppressive activity on the investigated immune response. Our results indicate that the reduced number and impaired functional properties of CD4+FOXP3+ T cells present in the BM of RA patients may favor the inflammatory process, which is observed in RA BM.
Subject(s)
Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/pathology , Bone Marrow/immunology , Bone Marrow/pathology , CD4 Antigens/metabolism , Forkhead Transcription Factors/metabolism , T-Lymphocytes/immunology , Adult , Aged , Female , Forkhead Transcription Factors/blood , Humans , Immunologic Memory , Interleukin-7 Receptor alpha Subunit/metabolism , Leukocyte Common Antigens/metabolism , Male , Middle Aged , Osteoarthritis/blood , Osteoarthritis/pathology , Receptors, CXCR4/blood , Receptors, CXCR4/metabolism , T-Lymphocytes, Regulatory/immunologyABSTRACT
Coronary heart disease (CHD) is the leading cause of human morbidity and mortality worldwide. MicroRNA (miRNA) profiling is an innovative method of identifying biomarkers for many diseases and may be a powerful tool in the diagnosis and treatment of CHD. The present study aimed to analyze the effects of miRNA (miR)381 on the inflammatory damage of endothelial cells during CHD. A total of 21 patients with CHD and 21 healthy control patients were enrolled in this study. Reverse transcriptionquantitative PCR, western blotting and immunofluorescence assays were conducted to examine the expression levels of miR381, CXC chemokine receptor type 4 (CXCR4), Bcl2, Bax, CleavedCaspases3 and 9, p38, ERK1/2 and JNK. Cell Counting Kit8, EdU and flow cytometry experiments were performed to evaluate cell proliferation and apoptosis. An ELISA was adopted to determine the expressions of inflammatory factors (interleukins8, 6 and 1ß, and tumor necrosis factorα). In addition, a dualluciferase reporter assay was used to determine the relationship between miR381 and CXCR4. Decreased miR381 expression and increased CXCR4 expression in the plasma were observed in the CHD group compared with the normal group, which indicated a negative relationship between miR381 and CXCR4. Overexpression of miR381 significantly promoted the proliferation and inhibited the apoptosis of oxidized lowdensity lipoprotein (OXLDL)induced human umbilical vein endothelial cells (HUVECs) through mitogenactivated protein kinase pathway by targeting and inhibiting CXCR4. Furthermore, overexpression of miR381 reduced the release of inflammatory factors in OXLDLinduced HUVECs. By contrast, reduced expression of miR381 exerted the opposite effects, which were subsequently reversed by silencing CXCR4 expression. Results from the present study indicated that miR381 was a CHDrelated factor that may serve as a potential molecular target for CHD treatment.
Subject(s)
Coronary Disease/genetics , MicroRNAs/genetics , Receptors, CXCR4/genetics , Signal Transduction , Aged , Apoptosis , Cell Proliferation , Coronary Disease/physiopathology , Coronary Disease/therapy , Female , Human Umbilical Vein Endothelial Cells/physiology , Humans , Male , Middle Aged , Receptors, CXCR4/bloodABSTRACT
OBJECTIVES: Investigation of mechanism related to excessive invasion of trophoblast cells in placenta accreta spectrum disorders (PAS) provides more strategies and ideas for clinical diagnosis and treatment. MATERIALS AND METHODS: Blood and placental samples were collected from included patients. The distribution and expression of CXCL12, CXCR4 and CXCR7 proteins in the paraffin of placental tissue in the included cases were analysed, and we analyse the downstream pathways or key proteins involved in cell invasion. RESULTS: Firstly, our results determined that CXCL12 and CXCR4/CXCR7 were increased in extravillous trophoblastic cell (CXCL12: P < .001; CXCR4: P < .001; CXCR7: P < .001), and the expression levels were closely related to the invasion depth of trophoblastic cells. Secondly, CXCL12 has the potential to become a biochemical indicator of PAS since the high expression of placental trophoblast CXCL12 may be an important source of blood CXCL12. Using lentivirus-mediated RNA interference and overexpression assay, it was found that both chemokine CXCL12 and receptor CXCR4/CXCR7 are associated with regulation of trophoblast cell proliferation, migration and invasion. Further results proved that through the activating the phosphorylation and increasing the expression of MLC and AKT proteins in the Rho/rock, PI3K/AKT signalling pathway, CXCL12, CXCR4 and CXCR7 could up-regulate the expression of RhoA, Rac1 and Cdc42 proteins to promote the migration and invasion of extravillous trophoblastic cell and ultimately formate the placenta accrete compare to the normal placenta. CONCLUSIONS: Our research proved that trophoblasts may contribute to a PAS-associated increase in CXCL12 levels in maternal blood. CXCL12 is not only associated with biological roles of PAS, but may also be potential for prediction of PAS.
Subject(s)
Chemokine CXCL12/blood , Placenta Diseases/blood , Receptors, CXCR4/blood , Receptors, CXCR/blood , Adult , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation/genetics , Chemokine CXCL12/genetics , Female , Gene Expression Regulation/genetics , Humans , Phosphorylation/genetics , Placenta Accreta/pathology , Placenta Diseases/genetics , Placenta Diseases/pathology , Pregnancy , Receptors, CXCR/genetics , Receptors, CXCR4/genetics , Trophoblasts/metabolism , Trophoblasts/pathologyABSTRACT
RATIONALE: B-1 cell-derived natural IgM antibodies against oxidation-specific epitopes on low-density lipoprotein are anti-inflammatory and atheroprotective. Bone marrow (BM) B-1a cells contribute abundantly to IgM production, yet the unique repertoire of IgM antibodies generated by BM B-1a and the factors maintaining the BM B-1a population remain unexplored. CXCR4 (C-X-C motif chemokine receptor 4) has been implicated in human cardiovascular disease and B-cell homeostasis, yet the role of B-1 cell CXCR4 in regulating atheroprotective IgM levels and human cardiovascular disease is unknown. OBJECTIVE: To characterize the BM B-1a IgM repertoire and to determine whether CXCR4 regulates B-1 production of atheroprotective IgM in mice and humans. METHODS AND RESULTS: Single-cell sequencing demonstrated that BM B-1a cells from aged ApoE-/- mice with established atherosclerosis express a unique repertoire of IgM antibodies containing increased nontemplate-encoded nucleotide additions and a greater frequency of unique heavy chain complementarity determining region 3 sequences compared with peritoneal cavity B-1a cells. Some complementarity determining region 3 sequences were common to both compartments suggesting B-1a migration between compartments. Indeed, mature peritoneal cavity B-1a cells migrated to BM in a CXCR4-dependent manner. Furthermore, BM IgM production and plasma IgM levels were reduced in ApoE-/- mice with B-cell-specific knockout of CXCR4, and overexpression of CXCR4 on B-1a cells increased BM localization and plasma IgM against oxidation specific epitopes, including IgM specific for malondialdehyde-modified LDL (low-density lipoprotein). Finally, in a 50-subject human cohort, we find that CXCR4 expression on circulating human B-1 cells positively associates with plasma levels of IgM antibodies specific for malondialdehyde-modified LDL and inversely associates with human coronary artery plaque burden and necrosis. CONCLUSIONS: These data provide the first report of a unique BM B-1a cell IgM repertoire and identifies CXCR4 expression as a critical factor selectively governing BM B-1a localization and production of IgM against oxidation specific epitopes. That CXCR4 expression on human B-1 cells was greater in humans with low coronary artery plaque burden suggests a potential targeted approach for immune modulation to limit atherosclerosis.
Subject(s)
B-Lymphocyte Subsets/metabolism , Bone Marrow Cells/metabolism , Coronary Artery Disease/blood , Immunoglobulin M/blood , Receptors, CXCR4/biosynthesis , Receptors, CXCR4/blood , Animals , Coronary Artery Disease/pathology , Humans , Mice , Mice, Inbred C57BL , Mice, TransgenicABSTRACT
OBJECTIVE: The diagnosis of RA patients remains a challenge, especially in ACPA-negative disease. Novel T-cell subsets, particularly Th17 may be useful, although data on Th17 frequency using flow cytometry in RA are conflicting. We investigated whether a novel epigenetic qPCR assay for the quantification of Th17 could differentiate patients with RA from those with symptoms evolving towards an alternative diagnosis. METHODS: We used a qPCR assay measuring the extent of the methylation at a key position in the IL-17 and CD4 genes. Assays were performed on whole blood from 49 healthy controls (HC) and 165 early arthritis clinic patients. Flow cytometry was further used to detect the expression of CXCR4 on Th17 cells. RESULTS: In 75 inflammatory arthritis patients who progressed to RA, the qPCR assays showed significantly fewer Th17 cells compared with 90 patients who did not (P<0.0001). Regression models demonstrated a high predictive value for RA development (75.8% correct prediction), and particularly for the ACPA-negative group (n = 125) where Th17 and swollen joint count (SJC) were the only predictors (73% correct prediction). The chemokine receptor CXCR4 had significantly higher expression on Th17 from early RA patients (n = 11) compared with HC (n = 15). CONCLUSION: The results of the epigenetic qPCR assay showed that low levels of Th17 cells were predictive of developing RA, particularly in the ACPA-negative patients. This could have value for insights into pathogenesis and management. The results suggest the recruitment of Th17 to the inflammatory disease site, consistent with high CXCR4 expression.
Subject(s)
Arthritis, Rheumatoid/diagnosis , Real-Time Polymerase Chain Reaction/statistics & numerical data , Th17 Cells/metabolism , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Female , Flow Cytometry , Humans , Male , Middle Aged , Predictive Value of Tests , Receptors, CXCR4/blood , Young AdultABSTRACT
OBJECTIVE: The stromal cell-derived factor-1α/cysteine-X-cysteine chemokine receptor 4 (SDF-1α/CXCR4) axis promotes neuroprotection and angiogenesis in animal studies. Few studies have investigated the potential clinical implications of the SDF-1α/CXCR4 axis in patients with acute ischemic stroke (AIS). We evaluated the prognostic values of the SDF-1α/CXCR4 axis in patients with proximal middle cerebral artery occlusion. METHODS: Fifty-five patients and 18 age- and sex-matched volunteers were enrolled. Baseline clinical characteristics and risk factors of stroke were recorded. Peripheral whole blood cells were double stained with anti-CD34 and anti-CXCR4 (CD184). CD34+CXCR4+ cells were analyzed by flow cytometry. Plasma SDF-1α levels were measured by enzyme-linked immunosorbent assay. RESULTS: In the AIS group, plasma SDF-1α levels and the number of circulating CD34+CXCR4+ cells were significantly higher than those in controls. Day 1 SDF-1α levels were negatively correlated with infarct volume (r = -0.521) and the initial National Institutes of Health Stroke Scale score (r = -0.489). SDF-1α levels (day 1: r = -0.514; day 3: r = -0.275; day 7: r = -0.375) and circulating CD34+CXCR4+ cells (day 7: r = -0.282) were inversely associated with the 90-day modified Rankin Scale score. CONCLUSION: The SDF-1α/CXCR4 axis has potential applications for predicting the clinical outcome of AIS.
Subject(s)
Brain Ischemia/blood , Chemokine CXCL12/blood , Receptors, CXCR4/blood , Stroke/blood , Aged , Antigens, CD34/metabolism , Brain Ischemia/complications , Brain Ischemia/diagnostic imaging , Female , Humans , Male , Middle Aged , Prognosis , Stroke/complications , Stroke/diagnostic imagingABSTRACT
Vulvovaginal candidiasis (VVC) is a common observed infection, affecting approximately 75% of women of reproductive age. Drug resistance represents a troublesome stumbling block associated with VVC therapy. Thus the aim of the present study was to provide information regarding the selection of potential drug targets for VVC. CXCR3-, CXCR4-, or CXCR/CXCR4 double-deficient mouse models of VVC were subsequently established, with changes to the load of Candida Albicans evaluated accordingly. The biological behaviors of the vaginal epithelial cells were characterized in response to the CXCR3-, CXCR4-, or CXCR3/CXCR4 double-knockout in vivo. Our initial observations revealed that in mice with VVC, CXCR3-, CXCR4-, or CXCR3 - CXCR4 double-knockout resulted in a decreased load of C. Albicans as well as reduced levels and proportion of Th17 cells. Proinflammatory cytokine production was found to be inhibited by CXCR3-, CXCR4-, or CXCR3/CXCR4 double-knockout whereby the mRNA and protein expressions CXCR3, CXCR4, IL-17, IL-6, and TNF-α exhibited decreased levels. CXCR3-, CXCR4-, or CXCR3/CXCR4 double-knockout appeared to function as positive proliferation factors, while playing a negative role in the processes of apoptosis and the cell cycle of vaginal epithelial cells. Taken together, the key findings of the study suggested that CXCR3/CXCR4 double-knockout could act to hinder the progression of VVC, highlighting its promise as a novel therapeutic target in the treatment of VVC. CXCR3 and CXCR4 genes may regulate Th17/IL-17 immune inflammatory pathways to participate in antifungal immunity.
Subject(s)
Candidiasis, Vulvovaginal/immunology , Candidiasis, Vulvovaginal/metabolism , Cytokines/biosynthesis , Inflammation Mediators/metabolism , Receptors, CXCR3/deficiency , Receptors, CXCR4/deficiency , Th17 Cells/pathology , Animals , Apoptosis , Candida albicans/physiology , Candidiasis, Vulvovaginal/blood , Candidiasis, Vulvovaginal/microbiology , Cell Cycle , Cell Proliferation , Cytokines/blood , Epithelial Cells/metabolism , Epithelial Cells/microbiology , Epithelial Cells/pathology , Female , Mice, Knockout , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, CXCR3/blood , Receptors, CXCR3/metabolism , Receptors, CXCR4/blood , Receptors, CXCR4/metabolism , Vagina/microbiology , Vagina/pathologyABSTRACT
OBJECTIVE: The role of CXCL12 and its receptor CXCR4 has not been fully examined in Parkinson's disease (PD). The purpose of this study was to investigate the role of CXCL12/CXCR4 in the peripheral blood of patients with PD and healthy controls. METHODS: CXCL12 serum levels and CXCR4 mRNA levels were measured in 30 PD patients and 40 controls using ELISA and real-time PCR, respectively. RESULTS: CXCL12 serum levels were significantly higher in PD patients compared to controls (p < 0.0001). Moreover, CXCR4 expression in peripheral blood mononuclear cells (PBMC) of PD patients was significantly increased compared to controls (p < 0.0001). CONCLUSIONS: Our findings provide new information on the expression of CXCL12/CXCR4 in PD. CXCR4 expression in PBMC or CXCL12 serum levels may be potential biomarkers of inflammation in PD patients.
Subject(s)
Chemokine CXCL12/blood , Leukocytes, Mononuclear/metabolism , Parkinson Disease/blood , Parkinson Disease/diagnosis , Receptors, CXCR4/blood , Aged , Biomarkers/blood , Female , Humans , Male , Middle AgedABSTRACT
AIM: To determine if CXCL12 (rs1801157) and CXCR4 (rs2228014) polymorphisms are associated with hepatocellular carcinoma (HCC) susceptibility, and detect their expressions in peripheral blood. METHODS: 206 HCC patients, 252 chronic hepatitis B patients, 221 liver cirrhosis patients and 275 healthy volunteers were recruited. Genes CXCL12 and CXCR4 were amplified and genotyped. Their expression in peripheral blood were detected. RESULTS: CXCL12 rs1801157 and CXCR4 rs2228014 polymorphisms were associated with increased susceptibility of HCC, and genotypes GA/AA and CT/TT may be risk factors of HCC (all p < 0.05). Expressions of CXCL12 and CXCR4 in peripheral blood from HCC patients increased significantly (p < 0.05). CONCLUSION: CXCL12 and CXCR4 polymorphisms may be risk factors for HCC, and they may be potential HCC markers.
Subject(s)
Biomarkers, Tumor/genetics , Carcinoma, Hepatocellular/genetics , Chemokine CXCL12/genetics , Liver Neoplasms/genetics , Receptors, CXCR4/genetics , Adult , Alleles , Biomarkers, Tumor/blood , Carcinoma, Hepatocellular/blood , Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/virology , Case-Control Studies , Chemokine CXCL12/blood , China/epidemiology , Female , Genetic Predisposition to Disease , Genotype , Hepatitis B virus/isolation & purification , Hepatitis B, Chronic/blood , Hepatitis B, Chronic/genetics , Hepatitis B, Chronic/virology , Humans , Incidence , Liver Cirrhosis/blood , Liver Cirrhosis/genetics , Liver Cirrhosis/virology , Liver Neoplasms/blood , Liver Neoplasms/epidemiology , Liver Neoplasms/virology , Male , Middle Aged , Polymorphism, Single Nucleotide , Receptors, CXCR4/blood , Sequence Analysis, DNAABSTRACT
Background: Squamous cell carcinoma (SCC) is the most frequent malignancy of the head and neck (HN) region. We here evaluated associations of stromal cell derived factor-1 (SDF-1or CXCL12) and its receptor, CXCR4, with HNSCCs. Materials and Methods: Sixty newly diagnosed HNSCC patients were enrolled in the patient group, and 28 healthy individuals in the control group. Plasma levels of CXCL12 and CXCR4 were measured using ELISA kits. Results: There was a significant difference in mean CXCL12, but not CXCR4, plasma levels between the patient and control groups (P=0.0001). No significant associations were found between mean plasma levels of either CXCL12 or CXCR4 with age, gender, tumor site, tumor size, lymph-node involvement or tumor stage. Conclusion: For the first time, our findings demonstrate a significant association between serum CXCL12 but not CXCR4 levels and HNSCCs.
Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Squamous Cell/pathology , Chemokine CXCL12/blood , Head and Neck Neoplasms/pathology , Receptors, CXCR4/blood , Carcinoma, Squamous Cell/blood , Case-Control Studies , Female , Follow-Up Studies , Head and Neck Neoplasms/blood , Humans , Male , Middle Aged , Prognosis , Survival RateABSTRACT
BACKGROUND: The chemokine receptors CXCR3 and CXCR4 are involved in the pathogenesis of fibrosis, a key feature of systemic sclerosis (SSc). It is hypothesized that immunoglobulin (Ig)G antibodies (abs) against these two receptors are present in patients with SSc and are associated with clinical findings. METHODS: Anti-CXCR3 and anti-CXCR4 ab levels were measured in 449 sera from 327 SSc patients and in 234 sera from healthy donors (HD) by enzyme-linked immunosorbent assay (ELISA). In SSc, ab levels were compared with clinical data in a cross-sectional and longitudinal setting. Protein expression of CXCR3 and CXCR4 on peripheral blood mononuclear cells (PBMCs) was analyzed in 17 SSc patients and 8 HD by flow cytometry. RESULTS: Anti-CXCR3 and anti-CXCR4 ab levels were different among SSc subgroups compared with HD and were highest in diffuse SSc patients. The ab levels strongly correlated with each other (r = 0.85). Patients with SSc-related interstitial lung disease (SSc-ILD) exhibited higher ab levels which negatively correlated with lung function parameters (e.g., r = -0.5 and r = -0.43 for predicted vital capacity, respectively). However, patients with deterioration of lung function showed lower anti-CXCR3/4 ab levels compared with those with stable disease. Frequencies and median fluorescence intensities (MFI) of CXCR3+ and CXCR4+ PBMCs were lower in SSc patients compared with HD and correlated with the severity of skin and lung fibrosis. They correlated with the severity of skin and lung fibrosis. CONCLUSIONS: Anti-CXCR3/4 abs and their corresponding receptors are linked with the severity of SSc-ILD. Antibody levels discriminate patients with stable or decreasing lung function and could be used for risk stratification.